OBJECTIVES: To measure progress against endometrioid endometrial carcinoma (EEC) in the Netherlands by analyzing trends in incidence, survival and mortality simultaneously. STUDY DESIGN: Descriptive study of incidence, survival and mortality rates of women with EEC in the Netherlands. Rates were age-standardized to the European standard population. Population-based data were extracted from the nationwide Dutch Cancer Registry (NCR) between 1989 and 2009. Mortality data since 1989 came from Statistics Netherlands. European age standardized incidence rates were calculated according to age, histology and stage. Five year relative survival estimates were calculated in four periods. Optimal progress against cancer is defined as decreasing incidence and/or improving survival accompanied by declining mortality. RESULTS: 80% of the 32,332 patients newly diagnosed with a corpus uteri malignancy had an EEC. The incidence of EEC rose significantly from 11/100,000 to 15/100,000, being most pronounced in women with FIGO stage IB and in the group with grade 1&2 tumours (P<0.05). Coinciding with the increased incidence, 5-year relative survival increased, especially for patients aged 60-74 years, in women with FIGO stage I, and in histology group grade 1&2, being 87%, 94% and 93%, respectively, during 2005-2009. CONCLUSION: The incidence of EEC (being 80% of corpus uteri cancer) increased markedly between 1989 and 2009, especially in women of 60-74 years. Five-year survival for patients with EEC increased from 83 to 85%. Progress against EEC has been less than was assumed previously, because mortality proportionally decreased only slightly, and because of the increasing incidence although survival improved.
OBJECTIVES: To measure progress against endometrioid endometrial carcinoma (EEC) in the Netherlands by analyzing trends in incidence, survival and mortality simultaneously. STUDY DESIGN: Descriptive study of incidence, survival and mortality rates of women with EEC in the Netherlands. Rates were age-standardized to the European standard population. Population-based data were extracted from the nationwide Dutch Cancer Registry (NCR) between 1989 and 2009. Mortality data since 1989 came from Statistics Netherlands. European age standardized incidence rates were calculated according to age, histology and stage. Five year relative survival estimates were calculated in four periods. Optimal progress against cancer is defined as decreasing incidence and/or improving survival accompanied by declining mortality. RESULTS: 80% of the 32,332 patients newly diagnosed with a corpus uteri malignancy had an EEC. The incidence of EEC rose significantly from 11/100,000 to 15/100,000, being most pronounced in women with FIGO stage IB and in the group with grade 1&2 tumours (P<0.05). Coinciding with the increased incidence, 5-year relative survival increased, especially for patients aged 60-74 years, in women with FIGO stage I, and in histology group grade 1&2, being 87%, 94% and 93%, respectively, during 2005-2009. CONCLUSION: The incidence of EEC (being 80% of corpus uteri cancer) increased markedly between 1989 and 2009, especially in women of 60-74 years. Five-year survival for patients with EEC increased from 83 to 85%. Progress against EEC has been less than was assumed previously, because mortality proportionally decreased only slightly, and because of the increasing incidence although survival improved.
Authors: Nicole C M Visser; Johan Bulten; Anneke A M van der Wurff; Erik A Boss; Carolien M Bronkhorst; Harrie W H Feijen; Joke E Haartsen; Hilde A D M van Herk; Ineke M de Kievit; Paul J J M Klinkhamer; Brenda M Pijlman; Marc P M L Snijders; Ingrid Vandenput; M Caroline Vos; Peter E J de Wit; Lonneke V van de Poll-Franse; Leon F A G Massuger; Johanna M A Pijnenborg Journal: BMC Cancer Date: 2015-06-30 Impact factor: 4.430
Authors: Tim Wollinga; Nicole P M Ezendam; Florine A Eggink; Marieke Smink; Dennis van Hamont; Brenda Pijlman; Erik Boss; Elisabeth J Robbe; Huy Ngo; Dorry Boll; Constantijne H Mom; Maaike A van der Aa; Roy F L P Kruitwagen; Hans W Nijman; Johanna M A Pijnenborg Journal: Gynecol Surg Date: 2018-02-27
Authors: Willem Jan van Weelden; Kristine Eldevik Fasmer; Ingvild L Tangen; Joanna IntHout; Karin Abbink; Antionius E van Herwaarden; Camilla Krakstad; Leon F A G Massuger; Ingfrid S Haldorsen; Johanna M A Pijnenborg Journal: BMC Cancer Date: 2019-06-07 Impact factor: 4.430
Authors: Casper Reijnen; Nicole Cm Visser; Jenneke C Kasius; Dorry Boll; Peggy M Geomini; Huy Ngo; Dennis Van Hamont; Brenda M Pijlman; Maria Caroline Vos; Johan Bulten; Marc Plm Snijders; Leon Fag Massuger; Johanna Ma Pijnenborg Journal: J Gynecol Oncol Date: 2019-09 Impact factor: 4.401
Authors: Daniel Ángel Rodríguez-Palacios; Sandra M Colorado-Yohar; Michel Velten; Ricardo J Vaamonde-Martín; Mónica Ballesta; María-Dolores Chirlaque Journal: Int J Environ Res Public Health Date: 2022-03-23 Impact factor: 3.390
Authors: Helen G Coleman; Cari M Kitahara; Liam J Murray; Kevin W Dodd; Amanda Black; Rachael Z Stolzenberg-Solomon; Marie M Cantwell Journal: Am J Epidemiol Date: 2013-10-03 Impact factor: 4.897